

Manuscript version: Author's Accepted Manuscript

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

Persistent WRAP URL:

<http://wrap.warwick.ac.uk/113482>

How to cite:

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk.

1 **Title Page**

2

3 **Title: Effect of a strategy of supraglottic airway device versus tracheal intubation**
4 **during out-of-hospital cardiac arrest on functional outcome: the AIRWAYS-2**
5 **randomized clinical trial.**

6

7 3rd Revision: 28th July 2018

8

9 **Authors:**

10

11 Jonathan R. Benger, MD¹

12 Kim Kirby, MRes^{1,2}

13 Sarah Black, DClinRes²

14 Stephen J. Brett, MD³

15 Madeleine Clout, BSc⁴

16 Michelle J. Lazaroo, MSc⁴

17 Jerry P. Nolan, MBChB^{5,6}

18 Barnaby C. Reeves, DPhil⁴

19 Maria Robinson, M.Ost²

20 Lauren J. Scott, MSc^{4,7}

21 Helena Smartt, PhD⁴

22 Adrian South, BSc (Hons)²

23 Elizabeth A. Stokes, DPhil⁸

24 Jodi Taylor, PhD^{4,5}

25 Matthew Thomas, MBChB⁹

26 Sarah Voss, PhD¹

27 Sarah Wordsworth, PhD⁸

28 Chris A. Rogers, PhD⁴

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

- ¹ University of the West of England, Glenside Campus, Bristol, UK
- ² South Western Ambulance Service NHS Foundation Trust, Exeter, UK
- ³ Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, UK
- ⁴ Clinical Trials and Evaluation Unit (CTEU), Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK
- ⁵ Bristol Medical School, University of Bristol, Bristol, UK
- ⁶ Department of Anaesthesia, Royal United Hospital, Bath, UK
- ⁷ CLAHRC West, Whitefriars, Bristol, UK
- ⁸ Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
- ⁹ Intensive Care Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Corresponding Author:

Professor Jonathan R Benger MD
Faculty of Health and Life Sciences
University of the West of England
Glenside Campus
Bristol. BS16 1DD
United Kingdom.
Tel: +44(0)1173421498 or +44(0)7801837030
E-mail: Jonathan.Benger@uwe.ac.uk

Word Count:

Abstract: 327
Main text: 3159

57 **Key Points**

58

59 **Question:** Does an initial strategy of a supraglottic airway device for advanced airway
60 management during non-traumatic out-of-hospital cardiac arrest (OHCA) result in a better
61 functional outcome compared with tracheal intubation?

62

63 **Findings:** In this cluster-randomized trial that included 1,523 paramedics and 9,296 patients
64 with OHCA, favorable functional outcome (modified Rankin Scale 0-3) at hospital discharge
65 or after 30 days (if still hospitalised) occurred in 6.4% in the supraglottic airway group versus
66 6.8% in the tracheal intubation group, a difference that was not statistically significant.

67

68 **Meaning:** In this study, a strategy of supraglottic airway device for advanced airway
69 management did not provide a superior functional outcome.

70

71

72

73 **Abstract**

74

75 **Importance:** The optimal approach to airway management during out-of-hospital cardiac
76 arrest (OHCA) is unknown.

77

78 **Objective:** To determine whether a supraglottic airway device (SGA) is superior to tracheal
79 intubation (TI) as the initial advanced airway management (AAM) strategy in adults with non-
80 traumatic OHCA.

81

82 **Design, Setting and Participants:** Cluster randomized trial of emergency medical services
83 clinicians (paramedics) from four ambulance services in England covering approximately 21
84 million people. Patients ≥ 18 years old, who had a non-traumatic OHCA and were attended
85 by a participating paramedic, were enrolled automatically under a waiver of consent between
86 June 2015 and August 2017. Follow-up ended in February 2018.

87

88 **Intervention:** Paramedics were randomised 1:1 to use TI (764 paramedics) or SGA (759
89 paramedics) for their initial AAM.

90

91 **Main Outcome Measures:** Primary outcome was modified Rankin Scale (mRS) at hospital
92 discharge or 30 days after OHCA, whichever occurred sooner. mRS was dichotomised; 0-3
93 (good outcome) or 4-6 (poor outcome; 6=death). Secondary outcomes included ventilation
94 success, regurgitation and aspiration.

95

96 **Results:** 9,296 eligible patients (SGA group: 4,886, TI group, 4,410) were enrolled (median
97 age 73 years; 3,373, 36.3% women), and mRS was known for 9,289. Characteristics were
98 similar between groups. 6.4% (311/4882) of patients in the SGA group and 6.8% (300/4407)
99 of patients in the TI group had a good outcome (adjusted risk difference (RD): -0.6%; 95%CI
100 -1.6% to +0.4%). Ventilation success was higher in the SGA strategy group (SGA: 87.4%;

101 4255/4868. TI: 79.0%; 3473/4397; adjusted RD: +8.3%; 95%CI +6.3% to +10.2%), however
102 patients allocated to TI were less likely to receive AAM (SGA: 85.2%; 4,161/4883. TI: 77.6%;
103 3,419/4404). Regurgitation and aspiration were not significantly different (regurgitation: SGA,
104 26.1%, 1268/4865; TI, 24.5%, 1072/4372; adjusted RD =+1.4% 95%CI -0.6% to +3.4%;
105 aspiration: SGA, 15.1%, 729/4824; TI, 14.9%, 647/4337; adjusted RD=+0.1%, 95%CI -1.5%
106 to +1.8%).

107

108 **Conclusions and Relevance:** Among patients with OHCA, randomization to a strategy of
109 advanced airway management with a supraglottic airway device compared with tracheal
110 intubation did not result in a favorable functional outcome at 30 days.

111

112 **Trial Registration:** ISRCTN No: 08256118.

113

114 **Introduction**

115

116 Out-of-hospital cardiac arrest (OHCA) is common, sudden and often fatal. In England during
117 2014, Emergency Medical Services (EMS) attempted resuscitation in almost 30,000 people;
118 only 25% achieved a return of spontaneous circulation (ROSC), and 8% were discharged
119 from hospital alive.¹ During OHCA few advanced life support (ALS) therapies have been
120 shown to improve outcome.² This is partly due to uncertainty about effective treatments, and
121 partly because it is challenging to conduct high-quality randomized clinical trials (RCTs) in
122 patients with OHCA. Consequently, many current clinical recommendations are based on
123 observational studies and expert consensus.³

124

125 Optimal airway management during OHCA is a key area of uncertainty, with very little high-
126 quality research on which to base treatment recommendations.⁴ Options range from basic or
127 minimal airway intervention to early advanced procedures that require training and expertise.

128

129 The advanced procedure of tracheal intubation (TI) has been considered a definitive airway
130 management technique.⁵ However, large observational studies (>100,000 patients) have
131 consistently favored basic airway management, e.g. bag-mask ventilation, over TI.^{6,7} The
132 introduction of supraglottic airways (SGAs) offers an alternative advanced airway
133 management (AAM) technique during OHCA. Insertion of a SGA is simpler and faster than
134 TI,⁸ and proficiency requires less training and ongoing practice.⁹ Observational evidence has
135 suggested a possible survival advantage for TI over SGAs.¹⁰ However, a large-scale RCT is
136 required to identify the optimal approach to AAM during OHCA.

137

138 The objective of this trial was to estimate the difference in modified Rankin Scale (mRS) at
139 hospital discharge or 30 days post OHCA, if sooner, between groups of patients managed
140 by paramedics randomized to use either SGA or TI as their initial advanced airway
141 management strategy following OHCA.

142 **Methods**

143

144 *Study Design*

145

146 The protocol and statistical analysis plan (SAP) for this parallel two-group multi-center
147 cluster-RCT are included in the online supplement, and the protocol has been published.¹¹

148

149 *Paramedic and Patient Population*

150

151 Paramedics were recruited from four large EMS provider organizations (ambulance services)
152 in England, which cover 21 million people (40% of England's population). The trial population
153 was adults who had a non-traumatic OHCA.

154

155 Patient inclusion criteria were: known or believed to be 18 years of age or older; non-
156 traumatic OHCA; attended by a paramedic participating in the trial who was either the first or
157 second paramedic to arrive at the patient's side; resuscitation commenced or continued by
158 EMS clinicians. Patient exclusion criteria were: detained in the Prison Service; previously
159 recruited to the trial (determined retrospectively); resuscitation deemed inappropriate
160 (using guidelines based on those of the Joint Royal Colleges Ambulance Liaison
161 Committee¹²); advanced airway already in place (inserted by another paramedic, doctor or
162 nurse) when a paramedic participating in the trial arrived at the patient's side; known to be
163 already enrolled in another pre-hospital RCT; patient mouth opening <2 cm.

164

165 Paramedics could not be blinded to their allocation and mechanisms were required to avoid
166 the risk of differential recruitment by paramedics based on the patient's perceived likely
167 outcome. Therefore, every eligible patient attended by a participating paramedic was
168 automatically enrolled in the study under a waiver of consent provided by the Confidentiality
169 Advisory Group (CAG: reference 14/CAG/1030). Ethics review and approval was provided

170 by South Central - Oxford C Research Ethics Committee (REC: reference 14/SC/1219),
171 which included a process of written informed consent for participating paramedics. A
172 disadvantage of automatic enrolment was that enrolled patients might not follow the study
173 protocol because the enrolling paramedic could not recall the protocol details (attendance at
174 an OHCA is relatively rare and stressful for paramedics), or the paramedic mistakenly
175 believed the patient to be ineligible.

176

177 *Randomization*

178

179 Because OHCA requires immediate treatment, randomizing patients at the point of OHCA
180 was considered impractical. Therefore, paramedics were randomized to use one of the two
181 AAM strategies for all eligible patients that they attended. This design, although clustered,
182 created many clusters with a small average number of patients, minimising the effect of
183 intra-cluster correlation and the risk of chance imbalances between groups.

184

185 Paramedics were randomised in a 1:1 ratio using a purpose-designed secure internet-based
186 system. The random sequence was computer generated in advance using varying block
187 sizes (range 4-8) and stratified by EMS provider organization (4 levels), paramedic
188 experience (2 levels) and distance from the paramedic's base ambulance station to the
189 usual destination hospital (2 levels).

190

191 *Intervention*

192

193 The intervention was the insertion of a second generation SGA with a soft non-inflatable cuff
194 (i-gel: Intersurgical, Wokingham, UK). Because of its speed and ease of insertion, this device
195 has become the most commonly used SGA during OHCA in England.^{13,14} The current
196 standard care pathway is TI using direct laryngoscopy; videolaryngoscopy is not used by
197 paramedics in England. A standard approach to airway management, from basic to

198 advanced techniques, was agreed by participating ambulance services. This included the
199 use of bag-mask ventilation (BMV) and simple airway adjuncts prior to AAM. Care
200 proceeded as usual for patients with OHCA enrolled in the trial, apart from the initial AAM.
201 All other care was delivered according to standard international resuscitation guidelines.³

202

203 Participating paramedics received additional training in their allocated AAM intervention
204 immediately after randomization. Training comprised theoretical and simulation-based
205 practice over 1 hour with a brief assessment to confirm competence. For TI a two-person
206 technique using an intubating bougie was recommended. End tidal carbon dioxide
207 monitoring was used to confirm correct device placement in all patients.

208

209 Protocol deviations could arise because paramedics have both strategies available to them.
210 Usual practice follows a “step-wise” approach from simple to more advanced techniques, but
211 paramedics have clinical freedom to adapt airway management during OHCA to the patient’s
212 anatomy, position and perceived needs. The trial protocol specified two attempts using the
213 allocated strategy before proceeding to the alternative, but paramedics had discretion to
214 deviate from the protocol on clinical grounds. Allowing discretion was necessary to avoid a
215 paramedic feeling obliged to undertake an intervention that they believed to be against the
216 patient’s best interests. This was also necessary to secure REC approval and professional
217 support.

218

219 *Outcomes*

220

221 The primary outcome was modified Rankin Scale (mRS) at hospital discharge, or at 30 days
222 if the patient remained in hospital. Patients were conveyed to and followed up in hospital
223 where mRS was collected by assessors blinded to treatment allocation. mRS is used widely
224 in OHCA research,^{15,16} and is usually dichotomised as good (0-3) or poor outcome/death (4-
225 6; 6 indicates death). The following secondary outcomes were collected for all eligible

226 patients, with all but the last 2 reported by participating paramedics: initial ventilation
227 success, defined as visible chest rise (classified as “yes” when AAM was not used);
228 regurgitation (stomach contents visible in the mouth or nose) and aspiration (stomach
229 contents visible below the vocal cords or inside a correctly placed tracheal tube or airway
230 channel of a SGA) (each classified as “no” when AAM was not used); loss of a previously
231 established airway (patients with AAM only); sequence of airway interventions delivered
232 (patients with AAM only); ROSC (i. patients with AAM only for ROSC during airway
233 management; ii. patients who died at the scene classified as “no” for ROSC at hospital
234 admission); airway management in place when ROSC was achieved, or resuscitation was
235 discontinued (patients with AAM only); chest compression fraction (in a sub-set of patients in
236 two EMS provider organizations); time to death.

237

238 Good quality, continuous CPR is associated with increased survival and improved function
239 following OHCA, and the concept of compression fraction has been developed to
240 standardise its measurement.¹⁷ Compression fraction was therefore measured and
241 compared in a sub-set of patients in two ambulance services using the “CPR Card” (Laerdal;
242 Stavanger, Norway), a small disposable device placed in the centre of the patient’s chest
243 during CPR. The device gives no feedback to the user but records data that can be retrieved
244 subsequently.

245

246 Resource use to support a cost effectiveness analysis and longer-term function were also
247 collected. These data will be reported separately.

248

249 *Sample Size*

250

251 In a previous feasibility study, 9% of patients survived to hospital discharge.¹⁸ No data were
252 available for mRS. However, death and poor functional outcome after OHCA are closely
253 related because death is the most common outcome.¹⁶ A 2% improvement in the proportion

254 of patients achieving a good outcome (mRS 0-3) was judged to be clinically important, and
255 consistent with the 2.4% difference in survival to hospital discharge between TI and SGAs
256 observed in retrospective data.¹⁹ This meant that 9,070 patients in total were needed to
257 detect a difference of 8% vs 10% at the 5% significance level and 90% power, after allowing
258 for clustering.¹¹

259

260 *Statistical Analysis*

261

262 Analysis of the primary outcome, and exploratory analyses of secondary outcomes, were
263 performed according to a pre-specified statistical analysis plan (SAP), which was finalised
264 before data lock and any comparative analysis, but after the end of recruitment due to staff
265 changes in the statistical team. Some typographical errors were corrected in version 2 and
266 some points were clarified, but no substantive changes were made. No comparative post-
267 hoc analyses were performed.

268

269 The primary analyses included all eligible patients with outcome data available (Tables
270 report details), except for the following secondary outcomes which only applied to those who
271 received AAM: loss of a previously established airway; ROSC during airway management;
272 airway management in place when ROSC was achieved or resuscitation was discontinued.
273 Chest compression fraction was only measured in small subset of patients. Patients were
274 grouped by the allocation of the first participating paramedic on scene (main analyses).
275 Analyses were adjusted for stratification factors as fixed effects. For binary outcomes,
276 mixed-effects logistic regression estimated odds ratios for the primary analysis, with
277 paramedic fitted as a random effect. Risk differences and risk ratios were also estimated
278 using generalised linear regression, with standard errors calculated using a sandwich
279 estimator to allow for clustering. Risk ratios are reported in the Supplement (eTable 7). For
280 time-to-event outcomes, Cox proportional-hazards regression was used. The proportionality
281 assumption, checked using Schoenfeld residuals, was met.

282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306

The level of missing data is given in footnotes to the Tables. Multiple imputation was not considered as the level of missing data was 7 patients (0.08%) for the primary outcome and less than 1.5% for all but one secondary outcome which had 6.4% missing data.

Two pre-specified exploratory sub-group analyses were performed for the primary outcome; i) Utstein comparator group (OHCA with a likely cardiac cause that is witnessed and has an initial rhythm amenable to defibrillation²⁰) versus non-comparator group, and ii) OHCA witnessed by EMS clinician or not. The treatment effect in sub-groups was compared by testing for an interaction between paramedic allocation and the sub-group variable.

Three pre-specified exploratory sensitivity analyses were performed for the primary outcome. The first extended the population to include patients attended by a participating paramedic who were not resuscitated (i.e. trial patients plus non-resuscitated patients). This was prompted by feedback from a pre-planned closed interim analysis of half the sample considered by the Data Monitoring and Safety Committee. The second and third sensitivity analyses, restricted to the cohort of patients who received AAM (as allocated and treatment received comparisons), were planned from the outset.

A 5% significance level (two-sided) was used. Groups were compared using Wald tests. No adjustment was made for multiple testing, so that secondary endpoints should be considered exploratory ²¹. All analyses were performed using Stata version 15.1 (StataCorp).

307 **Results**

308

309 *Participants, Baseline Characteristics and Protocol Adherence*

310

311 Overall, 1,523 paramedics were recruited and randomized. Of 13,462 potentially eligible
312 patients attended by a participating paramedic between June 2015 and August 2017, 4,166
313 (31%) were excluded and 9,296 (69%) were enrolled (Figure 1). Enrolled patients were
314 conveyed to 95 hospitals and followed-up to hospital discharge. Paramedics' allocation was
315 balanced (SGA: 759; TI: 764), but there were more patients in the SGA (n=4,886) than the
316 TI group (n=4,410). The proportions of patients with OHCA resuscitated (SGA: 51.6%,
317 7007/13587; TI: 50.5%, 6455/12789) and eligible (SGA; 69.7%, 4886/7006; TI: 68.3%;
318 4410/6454) were similar in the two groups.

319

320 Patient characteristics and cardiac arrest details were balanced between the two groups
321 (Table 1; eTables 1 and 2).

322

323 Fewer patients allocated to TI received AAM (77.6%; 3,419/4404, vs. 85.2%; 4,161/4883). TI
324 patients were also more likely to crossover to SGA as a result of clinical decision-making by
325 the paramedic on scene (Figure 2; eFigure 1, eTable 3).

326

327 *Primary Outcome*

328

329 Primary outcome data were available for 99.9% (9,289/9,296) of patients (Table 2); 6.4%
330 (311/4882) in the SGA group and 6.8% (300/4407) in the TI group had a good outcome
331 (mRS 0-3, odds ratio (OR) 0.918, 95% confidence interval (95%CI) 0.77-1.09; risk difference
332 (RD, SGA minus TI) -0.6%, 95%CI -1.6% to +0.4%; Figure 3 and eFigure 2).

333

334 *Exploratory Sensitivity Analyses*

335

336 Including patients attended by a participating paramedic who were not resuscitated did not
337 change the conclusion (SGA, 2.7%, 311/11462; TI, 2.8%, 300/10741; OR=0.959; 95%CI:
338 0.81-1.14. RD=-0.2%; 95%CI -0.6% to +0.3%; Figure 3, eTable 4). However, in the 7,576
339 (81%) patients who received AAM more patients in the SGA group had a good outcome
340 (SGA, 3.9%, 163/4158; TI, 2.6%, 88/3418; OR=1.57, 95%CI 1.18-2.07; RD=+1.4%; 95%CI
341 +0.5% to +2.2%). This effect was also observed in the analysis with patients grouped
342 according to the first AAM intervention received (SGA, 4.2%, 193/4630; TI, 2.0%, 58/2838;
343 OR=2.06, 95%CI 1.51-2.81; RD=+2.1%, 95%CI +1.2% to +2.9%).

344

345 *Exploratory Subgroup Analyses*

346

347 There was no interaction between allocation and either subgroup (Figure 3; Utstein
348 comparator group vs not, p=0.24; cardiac arrest witnessed by EMS clinician vs not, p=0.24).

349

350 *Secondary Outcomes*

351

352 Secondary outcomes are shown in Table 2 and eTable 5. The SGA treatment strategy was
353 significantly more successful in achieving ventilation after up to two attempts (SGA, 87.4%,
354 4255/4868; TI, 79.0%, 3473/4397; OR=1.92, 95%CI 1.66-2.22; RD=+2.1%, 95%CI +1.2% to
355 +2.9%). Regurgitation and aspiration at any time (i.e. before and/or after AMM) were similar
356 (regurgitation: SGA, 26.1%, 1268/4865; TI, 24.5%, 1072/4372; OR=1.08, 95%CI 0.96-1.20;
357 RD =+1.4% 95%CI -0.6% to +3.4%; aspiration: SGA, 15.1%, 729/4824; TI, 14.9%,
358 647/4337; OR=1.01, 95%CI 0.88-1.16; RD=+0.1%, 95%CI -1.5% to +1.8%).

359

360 The median time to death was not significantly different between the two groups (SGA: 67
361 minutes, n=4871. TI: 63 minutes, n=4400), and neither was the compression fraction in a

362 very small sample of 66 patients (SGA, median 86%, IQR 81-91%, n=34; TI, median 83%,
363 IQR 74%-89%, n=32; p=0.14; eTable 6).

364 **Discussion**

365 In this pragmatic cluster RCT no significant difference was found between TI and SGA in the
366 primary outcome of good outcome after OHCA for all trial patients.

367

368 Patients with a short duration of cardiac arrest and who receive bystander resuscitation
369 and/or defibrillation are considerably more likely to survive and are also less likely to require
370 AAM.²² This problem of confounding by indication is an important limitation of many large
371 observational studies that show an association between AAM and poor outcome in OHCA.²³
372 This study found that 21.1% (360/1704) of patients who received no AAM achieved a good
373 outcome compared to 3.3% (251/7576) of patients who received AAM.

374

375 Paramedics allocated to TI were less likely to use AAM than paramedics allocated to SGA.
376 TI is a more complex skill than SGA insertion and requires two practitioners, additional
377 equipment and good access to the patient's airway,²⁴ yet OHCA often occurs in locations
378 where patient access is challenging. TI has been associated with potential harms including
379 unrecognised oesophageal intubation, lengthy pauses in chest compressions and over-
380 ventilation.^{25,26} No evidence of a difference in compression fraction was found in a small sub-
381 sample of enrolled patients, but the potential for harm associated with TI persists.

382

383 At the outset, it was expected that most patients with a favourable outcome would not
384 receive AAM, and that some crossover would occur. For these reasons, two exploratory
385 sensitivity analyses were pre-specified only in patients who received AAM, even though
386 these analyses are susceptible to bias.²⁷ Patients who received AAM were similar in the two
387 groups (eTable 1; eTable 2), and a strategy of SGA first was associated with better
388 outcomes whenever AAM was undertaken by a trial paramedic (eTable 4), but the difference
389 between groups was less than the pre-specified clinically important 2% difference and less
390 than the minimal important difference of approximately 3% reported by others.²⁸ The SGA
391 first strategy also achieved initial ventilation success more often, although regurgitation and

392 aspiration during or after AAM were significantly more common in the SGA group.
393 Conversely, patients in the TI group were significantly more likely to regurgitate and aspirate
394 before AAM, possibly due to less frequent use of advanced techniques to secure the airway
395 in this group and the increased time required for TI compared to insertion of a SGA.

396

397 A recent RCT of French and Belgian patients with OHCA, comparing BMV with TI delivered
398 by physicians as part of an EMS team, proved inconclusive.²⁹ To our knowledge, no RCT
399 has compared BMV with an SGA in patients with OHCA. Reported rates of ventilation and TI
400 success have been higher in previous studies,^{29,30,31} but these have been based on selected
401 populations and practitioners with greater training and experience, including physicians. This
402 study reflects both the reality of current paramedic practice in England, and the challenges of
403 airway management in a patient group where regurgitation and poor airway access are
404 common.

405

406 Loss of a previously established airway occurred twice as frequently in the SGA group than
407 in the TI group. There are some cardiac arrest patients for whom effective ventilation cannot
408 be achieved with basic airway management techniques or an SGA, and for whom TI may be
409 the only way of achieving effective ventilation. The exact role of different advanced airway
410 management techniques in adults with OHCA, and the associated implications for skill
411 acquisition and maintenance, remain to be determined.

412

413 *Limitations*

414

415 This study has several limitations. First, the trial population included patients who did and did
416 not receive AAM, and the use of AAM was greater among paramedics in the SGA group
417 compared to those in the TI group which could result in confounding by indication.³² Second,
418 there was an imbalance in the number of patients in the two groups, probably due to unequal
419 distribution of high-recruiting paramedics in the two groups; it was not possible to stratify for

420 this because high-recruiting paramedics could not be identified in advance. Third, there was
421 crossover between groups, which was inevitable on practical and ethical grounds. Fourth,
422 although other elements of care (e.g. initial basic airway management and subsequent on-
423 scene and in-hospital care, such as targeted temperature management and access to
424 angiography) followed established guidelines, differences in these factors between groups
425 could have influenced the findings. Fifth, the participating paramedics were volunteers, and
426 their airway skills may not be representative of those who chose not to take part. Sixth, the
427 findings are applicable to use of the trial SGA in countries with similar EMS provision to
428 England, where paramedics attend most OHCA. The findings may not be applicable in
429 countries with physician-led EMS provision or to other SGAs which may have different
430 characteristics. However, the principles underpinning the insertion and function of all SGAs
431 are similar.

432

433 **Conclusions**

434

435 Among patients with OHCA, randomization to a strategy of advanced airway management
436 with a supraglottic airway device compared with tracheal intubation did not result in a
437 favorable functional outcome at 30 days.

438

439 **References**

440

- 441 1. Hawkes C, Booth S, Ji C, Brace-McDonnell SJ, Whittington A, Mapstone J, *et al.*
442 Epidemiology and outcomes from out-of-hospital cardiac arrests in England.
443 *Resuscitation* 2017;110:133-140.
- 444 2. Jentzer JC, Clements CM, Wright S, White RD, Jaffe AS. Improving survival from cardiac
445 arrest: a review of contemporary practice and challenges. *Ann Emerg Med*
446 2016;68(6):678-689.
- 447 3. Monsieurs KG, Nolan JP, Bossaert LL, Greif R, Maconochie IK, Nikolaou NI, *et al.*
448 European Resuscitation Council guidelines for resuscitation 2015. Section 1. Executive
449 summary. *Resuscitation* 2015;95:1-80.
- 450 4. Gwinnutt CL. Should we intubate patients during cardiopulmonary resuscitation? *BMJ*
451 2017;357:j1772.
- 452 5. Soar J, Nolan JP. Airway management in cardiopulmonary resuscitation. *Curr Opin Crit*
453 *Care* 2013;19(3):181–187.
- 454 6. Hasegawa K, Hiraide A, Chang Y, Brown DFM. Association of prehospital advanced
455 airway management with neurologic outcome and survival in patients with out-of-hospital
456 cardiac arrest. *JAMA* 2013;309(3):257-266.
- 457 7. Fouche PF, Simpson PM, Bendall J, Thomas RE, Cone DC, Doi SA. Airways in out-of-
458 hospital cardiac arrest: systematic review and meta-analysis. *Prehosp Emerg Care*
459 2014;18(2):244-56.
- 460 8. Kurola J, Harve H, Kettunen T, *et al.* Airway management in cardiac arrest – comparison
461 of the laryngeal tube, tracheal intubation and bag-valve mask ventilation in emergency
462 medical training. *Resuscitation* 2004;61:149–53.
- 463 9. Cook THB. Supraglottic airway devices: recent advances. *Contin Educ Anaesth Crit*
464 *Care Pain* 2011;11:56–61.

- 465 10. Wang HE, Szydlo D, Stouffer JA, *et al.* Endotracheal intubation versus supraglottic
466 airway insertion in out-of-hospital cardiac arrest. *Resuscitation* 2012;83:1061–6.
- 467 11. Taylor J, Black S, Brett SJ, Kirby K, Nolan JP, Reeves BC, *et al.* Design and
468 implementation of the AIRWAYS-2 trial: a multi-centre cluster randomised controlled trial
469 of the clinical and cost effectiveness of the i-gel supraglottic airway device versus
470 tracheal intubation in the initial airway management of out of hospital cardiac arrest.
471 *Resuscitation* 2016;109:25–32.
- 472 12. Joint Royal Colleges Ambulance Liaison Committee. Clinical practice guidelines 2016.
473 London: *Class Publishing*; 2016.
- 474 13. Duckett J, Fell P, Han K, Kimber C, Taylor C. Introduction of the i-gel supraglottic airway
475 device for prehospital airway management in a UK ambulance service. *Emerg Med J*
476 2014;31(6):505-7.
- 477 14. Häske D, Schempf B, Gaier G, Niederberger C. Performance of the i-gel™ during pre-
478 hospital cardiopulmonary resuscitation. *Resuscitation* 2013;84:1229-32.
- 479 15. Whitehead L, Perkins GD, Clarey A, Haywood KL. A systematic review of the outcomes
480 reported in cardiac arrest clinical trials: the need for a core outcome set. *Resuscitation*
481 2015;88:150-157.
- 482 16. Rittenberger JC, Raina K, Holm MB, Kim YJ, Callaway CW. Association between
483 Cerebral Performance Category, modified Rankin Scale, and discharge disposition after
484 cardiac arrest. *Resuscitation* 2011;82:1036–40.
- 485 17. Christenson J, Andrusiek D, Everson-Stewart S, Kudenchuk P, Hostler D, Powell J, *et al.*
486 Chest compression fraction determines survival in patients with out-of-hospital
487 ventricular fibrillation. *Circulation* 2009;120(13):1241–1247.
- 488 18. Bengner J, Coates D, Davies S, *et al.* Randomised comparison of the effectiveness of the
489 laryngeal mask airway supreme, i-gel and current practice in the initial airway
490 management of out of hospital cardiac arrest: a feasibility study. *Br J Anaesth*
491 2016;116:262–8.29.

- 492 19. Shin S, Ahn K, Song K, Park C, Lee E. Out-of-hospital airway management and cardiac
493 arrest outcomes: A propensity score matched analysis. *Resuscitation* 2012, 83(3): 313-
494 319.
- 495 20. Perkins GD, Jacobs IG, Nadkarni VM, Berg RA, Bhanji F, Biarent D, *et al.* Cardiac arrest
496 and cardiopulmonary resuscitation outcome reports: update of the Utstein Resuscitation
497 Registry Templates for out-of-hospital cardiac arrest: a statement for healthcare
498 professionals from a task force of the International Liaison Committee on Resuscitation
499 and the American Heart Association Emergency Cardiovascular Care Committee and
500 the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation.
501 *Resuscitation* 2015;96:328-40.
- 502 21. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments.
503 *Lancet* 2005; 365: 1591-5.
- 504 22. Andersen LW, Grossestreuer AV, Donnino MW. "Resuscitation time bias" - a unique
505 challenge for observational cardiac arrest research. *Resuscitation* 2018;125:79-82.
- 506 23. Carlson JN, Reynolds JC. Does advanced airway management improve outcomes in
507 adult out-of-hospital cardiac arrest? *Ann Emerg Med* 2014;64(2):163–164.
- 508 24. Higgs A, McGrath BA, Goddard C, Rangasami J, Suntharalingam G, Gale R. Guidelines
509 for the management of tracheal intubation in critically ill adults. *Br J Anaesth*
510 2018;120(2): 323e352.
- 511 25. Wang HE, Simeone SJ, Weaver MD, Callaway CW. Interruptions in cardiopulmonary
512 resuscitation from paramedic endotracheal intubation. *Ann Emerg Med* 2009;54(5):645–
513 652.e1.
- 514 26. Kramer-Johansen J, Wik L, Steen PA. Advanced cardiac life support before and after
515 tracheal intubation - direct measurements of quality. *Resuscitation* 2006;68(1):61–69.
- 516 27. Swanson SA, Robins JM, Miller M, Hernán MA. Selecting on treatment: a pervasive form
517 of bias in instrumental variable analyses. *Am J Epidemiol* 2015;181(3): 191–197.

- 518 28. Nichol, G, Brown SP, Perkins GD, Kim F. *et al.*, What change in outcomes after cardiac
519 arrest is necessary to change practice? Results of an international survey. *Resuscitation*,
520 2016. 107: p. 115-20
- 521 29. Jabre P, Penaloza A, Pinero D, Duchateau FX, Borron SW, Javaudin F, *et al.* Effect of
522 bag-mask ventilation vs endotracheal intubation during cardiopulmonary resuscitation on
523 neurological outcome after out-of-hospital cardiorespiratory arrest. A randomized clinical
524 trial. *JAMA* 2018;319(8):779-787.
- 525 30. Hubble MW, Brown L, Wilfong DA, Hertelendy A, Benner RW, Richards ME. A meta-
526 analysis of prehospital airway control techniques part I: orotracheal and nasotracheal
527 intubation success rates. *Prehosp Emerg Care* 2010;14(3):377-401.
- 528 31. Dyson K, Bray JE, Smith K, Bernard S, Straney L, Nair R, *et al.* Paramedic intubation
529 experience is associated with successful tube placement but not cardiac arrest survival.
530 *Ann Emerg Med* 2017;70(3):382–390.e1.
- 531 32. Kyriacou DN, Lewis RJ. Confounding by Indication in Clinical Research. *JAMA*.
532 2016;316(17):1818-1819.
533
534

535 **Acknowledgement:**

536

537 **Author Contributions:**

538

539 *Guarantors:* Bengner and Rogers had full access to all the data in the study and take
540 responsibility for the integrity of the data and the accuracy of the data analysis.

541 *Concept and design:* Bengner, Black, Brett, Kirby, Nolan, Reeves, Robinson, Rogers, Scott,
542 South, Stokes, Taylor, Thomas, Voss, Wordsworth.

543 *Acquisition, analysis, and interpretation of data:* All authors.

544 *Drafting of the manuscript:* Bengner.

545 *Critical revision of the manuscript for important intellectual content:* All authors.

546 *Statistical analysis:* Lazaroo, Scott, Smartt, Rogers (Clinical Trials and Evaluation Unit,
547 Bristol Medical School, University of Bristol, Bristol, UK)

548 *Technical and project support:* Clout, Taylor.

549

550 **Acknowledgement of non-author contributions:**

551

552 Megan Rhys, BSc Hons, South Western Ambulance Service NHS Foundation Trust, Exeter,
553 UK, lead research paramedic in feasibility study, supported paramedic engagement and
554 provided expertise when developing protocol.

555

556 Rachel Brophy, MSc, Clinical Trials and Evaluation Unit (CTEU), Bristol Medical School,
557 University of Bristol, Bristol, UK, assistant clinical trial coordinator, managed patient follow
558 up.

559

560 Jenny Lamb, BA Hons, Clinical Trials and Evaluation Unit (CTEU), Bristol Medical School,
561 University of Bristol, Bristol, UK, assistant clinical trial coordinator, managed patient follow
562 up.

563

564 Abby Willcox, PhD, Clinical Trials and Evaluation Unit (CTEU), Bristol Medical School,
565 University of Bristol, Bristol, UK, assistant clinical trial coordinator, managed patient follow
566 up.

567

568 Adam Wallis, South Western Ambulance Service NHS Foundation Trust, Exeter, UK,
569 provided financial management.

570

571 Tom Hill CIMA Adv Dip MA, South Western Ambulance Service NHS Foundation Trust,
572 Exeter, UK, provided financial management.

573

574 Tony West, AAT, South Western Ambulance Service NHS Foundation Trust, Exeter, UK,
575 provided financial management.

576

577 Jonathan Green, MRes, South Western Ambulance Service NHS Foundation Trust, Exeter,
578 UK, lead research paramedic for South Western Ambulance Service NHS Foundation Trust,
579 delivered regional paramedic recruitment and training, patient screening and data collection,
580 funded by NIHR grant.

581

582 Helen Hall, MCoP, East of England Ambulance Service NHS Trust, Melbourn, UK, research
583 paramedic for East of England Ambulance Service NHS Trust, delivered regional paramedic
584 recruitment and training, patient screening and data collection, funded by NIHR grant.

585

586 Richard Pilbery, MSc, Yorkshire Ambulance Service NHS Trust, Wakefield, UK, research
587 paramedic for Yorkshire Ambulance Service NHS Trust, delivered regional paramedic
588 recruitment and training, patient screening and data collection, funded by NIHR grant.

589

590 Gregory Adam Whitley, MSc, East Midlands Ambulance Service NHS Trust, Nottingham,
591 UK, research paramedic for East Midlands Ambulance Service NHS Trust, delivered
592 regional paramedic recruitment and training, patient screening and data collection, funded by
593 NIHR grant.

594

595 Theresa Foster, BSc (Hons), East of England Ambulance Service NHS Trust, Melbourn, UK,
596 Research Manager for East of England Ambulance Service NHS Trust, provided research
597 support and governance, no compensation received for contribution to the study.

598

599 Jane Shewan, RGN, BEd, MSc, Yorkshire Ambulance Service NHS Trust, Wakefield, UK,
600 Head of Research for Yorkshire Ambulance Service NHS Trust, provided research support
601 and governance.

602

603 Anne Spaight, MA, East Midlands Ambulance Service NHS Trust, Nottingham, UK, Head of
604 Clinical Governance, Audit and Research for East Midlands Ambulance Service NHS Trust,
605 provided research support and governance.

606

607 Marcus Bailey, BSc (Hons) Open, East of England Ambulance Service NHS Trust,
608 Melbourn, UK, consultant paramedic for East of England Ambulance Service NHS Trust,
609 acted as ambulance service Principal Investigator.

610

611 Steven Dykes, MB ChB, Yorkshire Ambulance Service NHS Trust, Wakefield, UK, Deputy
612 Medical Director for Yorkshire Ambulance Service NHS Trust, acted as ambulance service
613 Principal Investigator.

614

615 A. Niroshan Siriwardena, PhD, East Midlands Ambulance Service NHS Trust, Nottingham,
616 UK, research lead at East Midlands Ambulance Service NHS Trust, acted as ambulance
617 service Principal Investigator.

618

619 Lisa Grimmer, BSc, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, regional
620 research nurse in South Western region, coordinated and supported data collection in
621 receiving hospitals, funded by NIHR grant.

622

623 Katie Sweet, BSc (Hons), University Hospitals Bristol NHS Foundation Trust, Bristol, UK,
624 regional research nurse in South Western region, coordinated and supported data collection
625 in receiving hospitals, funded by NIHR grant.

626

627 Rosalyn Squire, BSc, University Hospitals Plymouth NHS Trust, Plymouth, UK, regional
628 research nurse in South Western region, coordinated and supported data collection in
629 receiving hospitals, funded by NIHR grant.

630

631 Prematie Andreou, BSc Hons, University Hospitals of Leicester NHS Trust, Leicester, UK,
632 regional research nurse in East Midlands region, coordinated and supported data collection
633 in receiving hospitals, funded by NIHR grant.

634

635 Lucy Ryan, MNurSci, Nottingham University Hospitals NHS Trust, Nottingham, UK, regional
636 research nurse in East Midlands region, coordinated and supported data collection in
637 receiving hospitals, funded by NIHR grant.

638

639 Sara Jones, BSc (Hons), Cambridge University Hospitals NHS Foundation Trust,
640 Cambridge, UK, regional research nurse in Eastern region, coordinated and supported data
641 collection in receiving hospitals, funded by NIHR grant.

642

643 Helen Foot, BA Hons, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK,
644 regional research nurse in Yorkshire region, coordinated and supported data collection in
645 receiving hospitals, funded by NIHR grant.

646

647 Simon Gates, PhD, University of Birmingham, Birmingham, UK, Chair and independent
648 member of Trial Steering Committee, received reimbursement of travel expenses incurred
649 during attendance at oversight meetings.

650

651 Charles Deakin, MA MD FRCA FRCP, University of Southampton, Southampton, UK,
652 independent member of Trial Steering Committee, received reimbursement of travel
653 expenses incurred during attendance at oversight meetings.

654

655 Keith Douglas, patient representative and independent member of Trial Steering Committee,
656 received reimbursement of travel expenses incurred during attendance at oversight
657 meetings.

658

659 Margaret Douglas, patient representative and independent member of Trial Steering
660 Committee, received reimbursement of travel expenses incurred during attendance at
661 oversight meetings.

662

663 Gavin D Perkins, MD, University of Warwick, Coventry, UK, independent member of Trial
664 Steering Committee, received reimbursement of travel expenses incurred during attendance
665 at oversight meetings.

666

667 Jasmeet Soar, FRCA FFICM FRCP, Southmead Hospital, North Bristol NHS Trust, Bristol,
668 UK, independent member of Trial Steering Committee, received reimbursement of travel
669 expenses incurred during attendance at oversight meetings.

670

671 Gordon Taylor, DPhil, MSc, BSc (Hons), University of Exeter Medical School, Exeter, UK,
672 Chair and independent member of Data Monitoring and Safety Committee, received
673 reimbursement of travel expenses incurred during attendance at oversight meetings.

674

675 Richard Lyon, MBE, MBChB (Hons), MD, FRCEM, MRCP, FCPPara, DipIMC (RCD), NHS
676 Lothian, Edinburgh, UK, independent member of Data Monitoring and Safety Committee,
677 received reimbursement of travel expenses incurred during attendance at oversight
678 meetings.

679

680 Andrew Newton, PhD, College of Paramedics, Bridgwater, UK, independent member of Data
681 Monitoring and Safety Committee, received reimbursement of travel expenses incurred
682 during attendance at oversight meetings.

683

684 Tom Quinn, MPhil, Kingston University and St George's, University of London, London, UK,
685 independent member of Data Monitoring and Safety Committee, received reimbursement of
686 travel expenses incurred during attendance at oversight meetings.

687

688 Helen Snooks, BSc (Hons), PhD, Swansea University, Swansea, UK, independent member
689 of Data Monitoring and Safety Committee, received reimbursement of travel expenses
690 incurred during attendance at oversight meetings.

691

692 **Conflict of Interest Disclosures:**

693

694 All authors have completed and submitted the ICMJE Form for Disclosure of Potential
695 Conflicts of Interest. Rogers salary was funded by a grant from the British Heart Foundation
696 until March 2017; part of Reeves salary was funded by grants from the National Institute for
697 Health Research. All other authors declare no conflicts of interest.

698

699 **Funding Statement:**

700 The trial was funded by the National Institute for Health Research (NIHR) Health Technology
701 Assessment (HTA) Programme (project number12/167/102), and supported by the NIHR

702 Comprehensive Research Networks. The study was not funded by any commercial
703 organizations or equipment manufacturers. The views and opinions expressed in this report
704 are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS or the
705 Department of Health and Social Care.

706 The funding organization had no role in the design and conduct of the study; collection,
707 management, analysis, and interpretation of the data; preparation, review, or approval of the
708 manuscript; and decision to submit the manuscript for publication.

709 This study was designed and delivered in collaboration with the Clinical Trials and
710 Evaluation Unit, a UKCRC registered clinical trials unit which, as part of the Bristol Trials
711 Centre, is in receipt of National Institute for Health Research CTU support funding.

712

713 **Supplementary Data:**

714

715 Supplementary data associated with this article can be found online

Table 1: Patient demography and cardiac arrest details

All trial patients	Randomised to TI (n=4,410)		Randomised to Trial SGA (n=4,886)	
	n	%	n	%
DEMOGRAPHY				
Male gender	2791/4410	63.3%	3132/4886	64.1%
Age (median, IQR)	74	(62, 83)	73	(61, 82)
INITIAL CARDIAC ARREST DETAILS				
Time from 999 call to first EMS clinician arrival (mins; median, IQR)	8	(5, 11)	7	(5, 11)
Time from first EMS clinician arrival to trial EMS clinician arrival (mins; median, IQR) ^[1]	0	(0, 4)	1	(0, 4)
Presenting rhythm				
Asystole	2356/4316	54.6%	2597/4791	54.2%
VF	979/4316	22.7%	1094/4791	22.8%
Pulseless VT	44/4316	1.0%	39/4791	0.8%
PEA	937/4316	21.7%	1061/4791	22.1%
Arrest witnessed	2788/4407	63.3%	3101/4883	63.5%
By bystander	2231/2788	80.0%	2493/3100	80.4%
By EMS clinician	557/2788	20.0%	607/3100	19.6%
Bystander/responder CPR before EMS clinician arrival	2774/4406	63.0%	3149/4883	64.5%
Bystander/responder defibrillation before EMS clinician arrival ^[2]	146/4390	3.3%	176/4863	3.6%
If yes, ROSC achieved	20/146	13.7%	27/176	15.3%
ON ARRIVAL OF STUDY EMS CLINICIAN				
Airway management in progress	1384/4389	31.5%	1463/4863	30.1%
BVM only	273/1383	19.7%	307/1463	21.0%
OPA and BVM	766/1383	55.4%	875/1463	59.8%
NPA and BVM	11/1383	0.8%	11/1463	0.8%
Trial SGA	262/1383	18.9%	190/1463	13.0%
Intubation	3/1383	0.2%	3/1463	0.2%
Other SGA	44/1383	3.2%	57/1463	3.9%
Mouth to mouth	8/1383	0.6%	10/1463	0.7%
Face shield/pocket mask	5/1383	0.4%	4/1463	0.3%
Suction	3/1383	0.2%	2/1463	0.1%
Other	8/1383	0.6%	4/1463	0.3%
Successful ventilations ongoing	1110/1372	80.9%	1154/1455	79.3%
Patient had ROSC on arrival	300/4393	6.8%	328/4862	6.8%

TI=Tracheal Intubation, SGA=Supraglottic Airway, IQR=Interquartile range, VF=Ventricular Fibrillation, VT=Ventricular Tachycardia, PEA=Pulseless Electrical Activity, EMS=Emergency Medical Services, CPR=Cardiopulmonary Resuscitation, ROSC=Return of Spontaneous Circulation, BVM=Bag Valve Mask, OPA=Oropharyngeal Airway, NPA=Nasopharyngeal Airway.

Missing data (randomised to TI, randomised to trial SGA): ^[1]4 patients (3, 1).

^[2]Where bystander/responder defibrillation occurred before EMS clinician arrival this was achieved using an automated external defibrillator (AED) available at scene.

All patients are grouped by the allocation of the first study EMS clinician on scene.

Table 2: Primary outcome (modified Rankin Scale at hospital discharge/30 days), survival status and main secondary outcomes

All trial patients	Randomised to TI (n=4,410)		Randomised to Trial SGA (n=4,886)		Estimate (95% CI)	p-value	ICC	Risk difference estimate (95% CI)	p-value
	n	%	n	%					
PRIMARY OUTCOME									
mRS (0 to 3; good recovery)					OR=0.92 (0.77, 1.09)	0.33	0.05	RD=-0.006 (-0.016, 0.004)	0.24
0 (no symptoms)	300/4407	6.8%	311/4882	6.4%					
1	124/4407	2.8%	117/4882	2.4%					
2	48/4407	1.1%	41/4882	0.8%					
3	50/4407	1.1%	58/4882	1.2%					
4	78/4407	1.8%	95/4882	1.9%					
5	46/4407	1.0%	45/4882	0.9%					
6 (deceased)	27/4407	0.6%	39/4882	0.8%					
	4034/4407	91.5%	4487/4882	91.9%					
SECONDARY OUTCOMES									
Survival status:									
Died at scene	2488/4407	56.5%	2623/4882	53.7%					
Died prior to ICU admission	1058/4407	24.0%	1226/4882	25.1%					
Died prior to ICU discharge	369/4407	8.4%	503/4882	10.3%					
Died prior to hospital discharge	120/4407	2.7%	138/4882	2.8%					
Survived to 30 days/hospital discharge	372/4407	8.4%	392/4882	8.0%					
Time to death (minutes; median, IQR, n)⁽¹⁾	63 (41,216)	4400	67 (41, 267)	4871	HR=0.97 (0.93, 1.02)	0.22			
Time to death 0-72 hours (minutes; n, median, IQR)⁽¹⁾	63 (41,205)	4400	67 (41, 246)	4871	HR=0.96 (0.92, 1.00)	0.07			
72 hour survival	575/4395	13.1%	664/4872	13.6%	OR=1.04 (0.92, 1.18)	0.54	0.02	RD=0.004 (-0.010, 0.019)	0.54
Initial ventilation success (up to two attempts at AAM)	3473/4397	79.0%	4255/4868	87.4%	OR=1.92 (1.66, 2.22)	<0.001	0.12	RD=0.083 (0.063, 0.102)	<0.001
TI	1891/2723	69.4%	92/116	79.3%					
Trial SGA	542/617	87.8%	3412/3994	85.4%					
Other SGA	55/72	76.4%	29/36	80.6%					

All trial patients	Randomised to TI (n=4,410)		Randomised to Trial SGA (n=4,886)		Estimate (95% CI)	p-value	ICC	Risk difference estimate (95% CI)	p-value
	n	%	n	%					
Any loss of a previously established airway ^[2]	153/3081	5.0%	412/3900	10.6%	OR=2.29 (1.86, 2.82)	<0.001	0.07	RD=0.059 (0.046, 0.072)	<0.001
TI	70/2149	3.3%	33/570	5.8%					
Trial SGA	84/981	8.6%	389/3455	11.3%					
Other SGA	5/171	2.9%	3/33	9.1%					
Regurgitation at any time	1072/4372	24.5%	1268/4865	26.1%	OR=1.08 (0.96, 1.20)	0.21	0.06	RD=0.014 (-0.006, 0.034)	0.17
Aspiration at any time	647/4337	14.9%	729/4824	15.1%	OR=1.01 (0.88, 1.16)	0.84	0.08	RD=0.001 (-0.015, 0.018)	0.86
Regurgitation before initial SGA/TI attempt	923/4379	21.1%	846/4869	17.4%					
Aspiration before initial SGA/TI attempt	589/4355	13.5%	532/4840	11.0%					
Regurgitation during or after initial SGA/TI attempt	543/4361	12.5%	875/4857	18.0%					
Aspiration during or after initial SGA/TI attempt	304/4344	7.0%	473/4829	9.8%					
Admitted to ED/hospital	1922/4410	43.6%	2263/4886	46.3%					
ROSC on ED/hospital arrival	1249/4404	28.4%	1495/4880	30.6%	OR=1.12 (1.02, 1.23)	0.02	0.01	RD=0.022 (0.003, 0.042)	0.03
Survived to ED discharge	861/1919	44.9%	1033/2259	45.7%					

TI=Tracheal Intubation, SGA=Supraglottic Airway device, CI=Confidence Interval, ICC=Intracluster correlation coefficient, OR=odds ratio, RD=risk difference, HR=Hazard ratio, mRS=modified Rankin Scale score, ICU=Intensive Care Unit, IQR=Interquartile Range, AAM=advanced airway management, ED=Emergency department, ROSC=Return of spontaneous circulation, EMS=Emergency medical services.

Note:

Odds ratios and risk differences are adjusted for stratification factors fitted as fixed effects. Odds ratios were obtained from a mixed effects logistic regression model with study EMS clinician fitted as a random effect. Risk differences were obtained by fitting a generalised linear model (binomial family and identity link) with standard errors adjusted for clustering. The hazard ratios are adjusted for EMS clinician experience and distance from usual hospital and stratified by EMS provider organisation with standard errors adjusted for clustering. Wald p-values are displayed.

^[1] Patients who survived to ICU discharge but did not consent to active or passive follow-up were censored at ICU discharge because research approvals did not permit analysis of subsequent data, apart from the mRS.

^[2] Trial patients with at least one AAM attempt only

All patients are grouped by the allocation of the first study EMS clinician on scene.

Figure 1 Flow of study EMS clinicians and patients

Submitted separately.

Figure 2 Interventions received and patient outcome by study allocation

Submitted separately.

Figure 3 Forest plot of primary outcome results (mRS at hospital discharge/30 days)

Submitted separately, notes for figure below

mRS=Modified Rankin Scale, TI=Tracheal Intubation, SGA=Supraglottic Airway device, OR=Odds Ratio, CI=Confidence Interval, EMS=Emergency Medical Services.

Odds ratios are estimated from a mixed effects logistic regression model, with stratification factors fitted as fixed effects and study EMS clinician as a random effect). Wald p-values are displayed.

The size of the point estimate (grey dot) is proportional to the number of patients included

Note:

Patients are grouped by the allocation of the first study EMS clinician on scene.

eFigure 2 displays the breakdown of the mRS scores in the form of horizontally stacked bar charts.

n/N is displayed where n is the number of patients with a score of 0-3 (good recovery) and N is the total number in that group.

[1] All trial patients.

[2] All trial patients. Patients whose cardiac arrest was recorded as not witnessed are included in the Utstein non-comparator group

[3] All trial patients. Patients whose cardiac arrest was recorded as not witnessed are included in the not witnessed by ambulance staff group

[4] All trial patients plus patients attended by a study EMS clinician who were not resuscitated.

Missing data (randomised to TI, randomised to SGA): [1] 7 patients (3, 4). [2] 103 patients (52, 51). [3] 7 patients (3, 4). [4] 4 patients (1, 3).